[go: up one dir, main page]

WO1997011666A3 - Use of 2-mercaptoethanolamine (2-mea) and related aminothiol compounds and copper(ii)-3,5 di-isopropyl salicylates and related compounds in the prevention and treatment of various diseases - Google Patents

Use of 2-mercaptoethanolamine (2-mea) and related aminothiol compounds and copper(ii)-3,5 di-isopropyl salicylates and related compounds in the prevention and treatment of various diseases Download PDF

Info

Publication number
WO1997011666A3
WO1997011666A3 PCT/IB1996/001059 IB9601059W WO9711666A3 WO 1997011666 A3 WO1997011666 A3 WO 1997011666A3 IB 9601059 W IB9601059 W IB 9601059W WO 9711666 A3 WO9711666 A3 WO 9711666A3
Authority
WO
WIPO (PCT)
Prior art keywords
compounds
mercaptoethanolamine
mea
copper
prevention
Prior art date
Application number
PCT/IB1996/001059
Other languages
French (fr)
Other versions
WO1997011666A2 (en
Inventor
Samir Chachoua
Original Assignee
Samir Chachoua
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Samir Chachoua filed Critical Samir Chachoua
Priority to JP9513260A priority Critical patent/JPH11514990A/en
Priority to AU69990/96A priority patent/AU6999096A/en
Priority to EP96931214A priority patent/EP0858327A2/en
Publication of WO1997011666A2 publication Critical patent/WO1997011666A2/en
Publication of WO1997011666A3 publication Critical patent/WO1997011666A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/145—Amines having sulfur, e.g. thiurams (>N—C(S)—S—C(S)—N< and >N—C(S)—S—S—C(S)—N<), Sulfinylamines (—N=SO), Sulfonylamines (—N=SO2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/42—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum viral
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • AIDS & HIV (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Transplantation (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

New therapeutic compositions and applications of 2-mercaptoethanolamine (2-MEA) and related aminothiols and copper(II)-3,5 di-isopropyl salicylates, solely or in combination with other factors, agents, or processes that are physical, chemical and/or biological based are disclosed. These include precursors, intermediates, end products, catalysts, promoters and/or any factors, agents, or processes involved directly or indirectly from initial application of the compositions to the final result.
PCT/IB1996/001059 1995-09-25 1996-09-25 Use of 2-mercaptoethanolamine (2-mea) and related aminothiol compounds and copper(ii)-3,5 di-isopropyl salicylates and related compounds in the prevention and treatment of various diseases WO1997011666A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
JP9513260A JPH11514990A (en) 1995-09-25 1996-09-25 Use of 2-mercaptoethanolamine (2-MEA) and related aminothiol compounds and copper 3,5-diisopropylsalicylate (II) and related compounds for preventing and treating various diseases
AU69990/96A AU6999096A (en) 1995-09-25 1996-09-25 Use of 2-mercaptoethanolamine (2-mea) and related aminothiol compounds and copper(ii)-3,5 di-isopropyl salicylates and related compounds in the prevention and treatment of various diseases
EP96931214A EP0858327A2 (en) 1995-09-25 1996-09-25 Use of 2-mercaptoethanolamine (2-mea) and related aminothiol compounds and copper(ii)-3,5 di-isopropyl salicylates and related compounds in the prevention and treatment of various diseases

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US428195P 1995-09-25 1995-09-25
US60/004,281 1995-09-25

Publications (2)

Publication Number Publication Date
WO1997011666A2 WO1997011666A2 (en) 1997-04-03
WO1997011666A3 true WO1997011666A3 (en) 1997-06-19

Family

ID=21710013

Family Applications (2)

Application Number Title Priority Date Filing Date
PCT/IB1996/001059 WO1997011666A2 (en) 1995-09-25 1996-09-25 Use of 2-mercaptoethanolamine (2-mea) and related aminothiol compounds and copper(ii)-3,5 di-isopropyl salicylates and related compounds in the prevention and treatment of various diseases
PCT/IB1996/001115 WO1997011667A2 (en) 1995-09-25 1996-09-25 Therapeutic applications using horse serum

Family Applications After (1)

Application Number Title Priority Date Filing Date
PCT/IB1996/001115 WO1997011667A2 (en) 1995-09-25 1996-09-25 Therapeutic applications using horse serum

Country Status (5)

Country Link
EP (2) EP0858327A2 (en)
JP (1) JPH11514990A (en)
AU (2) AU7143196A (en)
CA (2) CA2233015A1 (en)
WO (2) WO1997011666A2 (en)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5994409A (en) * 1997-12-09 1999-11-30 U.S. Bioscience, Inc. Methods for treatment of neuro--and nephro--disorders and therapeutic toxicities using aminothiol compounds
US6384259B1 (en) 1998-11-16 2002-05-07 Medimmune Oncology, Inc. Stable amorphous amifostine compositions and dosage form
PT1220678E (en) * 1999-10-04 2007-06-11 John Carter Pharmaceutical compositions containing copper, salicylic acid and vitamin c
US7927612B2 (en) 2000-01-19 2011-04-19 Baofa Yu Combinations and methods for treating neoplasms
US6811788B2 (en) 2000-01-19 2004-11-02 Baofa Yu Combinations and methods for treating neoplasms
US6506413B1 (en) * 2001-04-30 2003-01-14 Joseph C. Ramaekers Compositions for treating animal diseases and syndromes
US7053072B2 (en) 2001-05-11 2006-05-30 Medimmune Oncology, Inc. Methods for the administration of amifostine and related compounds
FR2825923B1 (en) * 2001-06-15 2006-04-07 Oreal NO-SYNTHASE INHIBITOR AND USES
KR20030077743A (en) * 2002-03-26 2003-10-04 변현규 The serum of pregancy mare
US7629333B2 (en) 2002-03-29 2009-12-08 Medimmune, Llc Stable amorphous amifostine compositions and methods for the preparation and use of same
AU2002353346A1 (en) * 2002-09-10 2004-04-30 Samir Chachoua Induced remission therapy
GB2398497A (en) * 2003-02-19 2004-08-25 Walcom Animal Science Composition for improving immunity of animals
US9125874B2 (en) 2007-11-30 2015-09-08 The Ramaekers Family Trust Administration of transfer factor for improving reproductive health
CN101138634A (en) 2006-09-07 2008-03-12 于保法 Composition for treating tumour
EP2278984A4 (en) 2007-11-30 2013-02-27 Ramaekers Family Trust Compositions and methods for enhancing fertility
US20110311557A1 (en) * 2009-02-11 2011-12-22 Martin Heath Bluth Reciprocal serum/plasma exchange for the treatment of cancer
SG11201704175WA (en) 2014-11-26 2017-06-29 Baofa Yu Hapten-enhanced chemoimmunotherapy by ultra-minimum incision personalized intratumoral chemoimmunotherapy

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4952607A (en) * 1982-05-27 1990-08-28 International Copper Research Association, Inc. Copper complex for treating cancer
US5488042A (en) * 1992-03-13 1996-01-30 Arch Development Corporation Method for protection against genotoxic mutagenesis

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4228127A (en) * 1978-10-06 1980-10-14 International Radioimmune Systems, Inc. Kit for detecting human chorionic gonadotropin
US5057314A (en) * 1988-09-30 1991-10-15 Whitfill Craig E Low molecular weight antiviral factors
US5310653A (en) * 1989-10-24 1994-05-10 Board Of Regents, The University Of Texas System Tumor marker protein and antibodies thereto for cancer risk assessment or diagnosis
DE4236069A1 (en) * 1992-10-26 1994-04-28 Werner Dr Bergmann Homeopathic medicaments for treating HIV infections - prepd. by dilution of infected serum
WO1994028934A1 (en) * 1993-06-07 1994-12-22 Center For Special Immunology Adoptive immune reconstitution treatment for patients with acquired immunodeficiencies

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4952607A (en) * 1982-05-27 1990-08-28 International Copper Research Association, Inc. Copper complex for treating cancer
US5488042A (en) * 1992-03-13 1996-01-30 Arch Development Corporation Method for protection against genotoxic mutagenesis

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
ANTICANCER RES., 1989, Vol. 9, CRISPENS et al., "Evaluation of Combinations of CuDIPS, Tween 80 and Cyclophosphamide as Therapy for Reticulum Cell Sarcoma in SJL/J Mice", pages 357-360. *
BIOCHEMICAL PHARMACOL., 1983, Vol. 32, No. 22, KENSLER et al., "Inhibition of Oxygen Radical Metabolism in Phorbol Ester-activated Polymorphonuclear Leukocytes by an Antitumor Promoting Copper Complex With Superoxide Dismutase-mimetic Activity", pages 3485-3487. *
BIOCHIM. BIOPHYS. ACTA., 1994, Vol. 1223, JEITNER et al., "Thiol-bearing Compounds Selectively Inhibit Protein Kinase C-dependent Oxidative Events and Proliferation of Human T Cells", pages 15-22. *
CARCINOGENESIS, 1988, Vol. 9, No. 4, REINERS et al., "Survey of Cytotoxicities and Antimutagenic and antitumor Initiating Activities of Cu(II)(3,5-diisopropylsalicylate)2 and its Analogs in a Keratinocyte-mediated Mutation Assay and the Murine Skin Multistage Carcinogenesis Model", pages 629-632. *
CHEMICAL ABSTRACTS, Vol. 85, No. 3, issued 19 July 1976 (Columbus, OH, USA), page 34, Abstract No. 13848n, GRAZIENE A., "Immunomorphalogical and Ultrastructural Study of Lymphoid Tissue During the Administration of D-penicillamine Under Experimental Autoimmune Conditions"; & VOPR. REVM., 1975, (4), 21-6 (Russ). *
CHEMICAL ABSTRACTS, Volume 99, No. 23, issued 05 December 1983, (Columbus, OH, USA), page 641, Abstract No. 193577u, TRYFIATES G.P., "Control of Tumor Growth by Pyridoxine Restriction of Treatment With an Antivitamin Agent"; & CANCER DETECT. PREV., 1981, 4(1-4), 159-64 (Eng.). *
J. CLIN. INVEST., May 1994, Vol. 93, BERGAMINI et al., "Cystamine Potently Suppresses In Vitro HIV Replication in Acutely and Chronically Infected Human Cells", pages 251-257. *

Also Published As

Publication number Publication date
EP0858327A2 (en) 1998-08-19
CA2233445A1 (en) 1997-04-03
WO1997011666A2 (en) 1997-04-03
CA2233015A1 (en) 1997-04-03
AU7143196A (en) 1997-04-17
WO1997011667A3 (en) 1997-06-12
WO1997011667A2 (en) 1997-04-03
JPH11514990A (en) 1999-12-21
AU6999096A (en) 1997-04-17
EP0853486A2 (en) 1998-07-22
EP0853486A4 (en) 2001-09-26

Similar Documents

Publication Publication Date Title
WO1997011666A3 (en) Use of 2-mercaptoethanolamine (2-mea) and related aminothiol compounds and copper(ii)-3,5 di-isopropyl salicylates and related compounds in the prevention and treatment of various diseases
AU2639695A (en) Novel uses of triplex forming oligonucleotides for the treatment of human diseases
EP1029540A3 (en) Use of droloxifene for the treatment of cardiovascular diseases
ZA969820B (en) Fluorinated or hydroxylated phenylimidazolidines, preparation process and intermediates, use as medicaments, new use and pharmaceutical compositions.
HUT76258A (en) Compositions comprising dna damaging agents and p53, and methods for uses thereof
IL170120A (en) 1,2,4-triazine compounds, their use for preparation of medicaments for treating or preventing hiv, pharmaceutical compositions comprising the same and processes for their preparation
BR9711194A (en) Use of chelating agent clioquinol for the manufacture of a pharmaceutical composition for the treatment of alzheimer&#39;s disease.
HUP9800467A3 (en) Use of hyaluronic acid for producing pharmaceutical compns. for the treatment of interstitial cystitis
PL346904A1 (en) Pharmaceutical agents for the treatment of parkinson&#39;s disease, adhd and microadenomas
AU4069095A (en) Medicaments for the treatment of restenosis and arterial sclerosis
ZA977310B (en) Transdermal propentofylline compositions for the treatment of Alzheimer&#39;s disease.
WO1998059040A3 (en) Human catalytic telomerase sub-unit and its diagnostic and therapeutic use
HUP9904317A3 (en) Use of 1-hydroxy-2-pyridones for producing pharmaceutical compositions suitable for the treatment of skin diseases
HU9600455D0 (en) Use of quinoxalines combined with protease-inhibiting compounds for producing pharmaceutical compositions for treating hiv infections
IT1290781B1 (en) ACTIVE THERAPEUTIC AGENT FOR THE TREATMENT OF NEURONAL DEGENERATIVE DISEASES.
ZA962715B (en) Pharmaceutical agents for the treatment of Alzheimer&#39;s disease.
AU8851298A (en) L-threonate ferrous, as well as pharmaceutical composition and use for improvingand treating human anemia thereof
NL300083I1 (en) 1-Beta-D-ribofuranosyl-1,2,4-triazole-3-carboxamide for the preparation of a medicament for the medical treatment of humans.
AU7982098A (en) Use of beta2-adrenoceptor agonists for the manufacture of a medicament for the treatment of scoliosis
EP0755262A4 (en) Composition for the treatment of lung disease
SI0778025T1 (en) Use of 8,9-dehydroestrone for the manufacture of a medicament for the treatment of diseases caused by free radicals
DE59300883D1 (en) Process for the preparation of dianthraquinone-N, N&#39;-dihydroazine and its chlorination products.
FI961494L (en) Pharmaceutical compositions and their use, especially for the treatment of neurodegenerative diseases
BR9507732A (en) Pharmaceutical composition for the treatment of glaucoma
AU6819898A (en) Oxygen anion radicals and/or therapeutic preparations containing their reaction or breakdown products, and use of such preparations in the treatment of parkinson&#39;s disease

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AU BB BG BR CA CN CU CZ EE FI GE HU IS JP KE KG KP KR LK LR LT LV MD MG MK MN MW MX NO NZ PL RO SG SI SK TR TT UA UZ VN AM AZ BY KG KZ MD RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): KE LS MW SD SZ UG AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

AK Designated states

Kind code of ref document: A3

Designated state(s): AL AM AU BB BG BR CA CN CU CZ EE FI GE HU IS JP KE KG KP KR LK LR LT LV MD MG MK MN MW MX NO NZ PL RO SG SI SK TR TT UA UZ VN AM AZ BY KG KZ MD RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): KE LS MW SD SZ UG AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
ENP Entry into the national phase

Ref document number: 2233445

Country of ref document: CA

Ref country code: CA

Ref document number: 2233445

Kind code of ref document: A

Format of ref document f/p: F

ENP Entry into the national phase

Ref country code: JP

Ref document number: 1997 513260

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 1996931214

Country of ref document: EP

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWP Wipo information: published in national office

Ref document number: 1996931214

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1996931214

Country of ref document: EP